MetaCap

Seres Therapeutics (MCRB) vs Neuphoria Therapeutics (NEUP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Neuphoria Therapeutics is the larger company by market cap ($12.7 million vs $12.6 million), about 1.0 times the size. Seres Therapeutics converts more of its revenue into profit, with a net margin of 721.9% versus -1145.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MCRB-54.41%NEUP-31.29%
+5%-26%-57%
Oct 7, 20261 yearNov 20, 2026
MCRB-54.24%NEUP-30.06%
+5%-26%-57%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MCRB versus NEUP key metrics
MetricMCRBNEUP
Share price$1.24$2.35
Market cap$12.64M$12.72M
1-day change-6.77%+1.29%
YTD return—-39.43%
1-year return—-47.31%
EPS (TTM)$-5.01$-2.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$789.00K$1.17M
Revenue growth (YoY)—-92.50%
Net income (latest FY)$5.70M$-13.45M
Operating margin-11910.14%-1401.09%
Net margin721.93%-1145.66%
52-week high$18.86$5.53
52-week low$1.20$2.26
Distance from 52-week high-93.43%-57.50%
Analyst consensusnonenone
Avg. price target upside+1270.97%—
Average volume74.83K26.53K
Shares outstanding10.20M5.41M
Employees661
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Seres Therapeutics is more profitable, keeping 721.9 cents of every revenue dollar as net income versus -1145.7 cents for Neuphoria Therapeutics.

About Seres Therapeutics

MCRB stock →

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.

Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees

About Neuphoria Therapeutics

NEUP stock →

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

MCRB vs NEUP FAQ

Which is bigger, Seres Therapeutics or Neuphoria Therapeutics?

Neuphoria Therapeutics (NEUP) is larger, with a market capitalization of $12.72M compared with $12.64M for Seres Therapeutics (MCRB).

Are Seres Therapeutics and Neuphoria Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons